CJC-1295 vs Ipamorelin at a glance
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Also known as | with or without DAC | selective GHRP |
| Category | Growth Hormone & Muscle | Growth Hormone & Muscle |
| Format | SubQ | SubQ |
| Research level | Beginner | Beginner |
| Research sizes | 2 mg vial, 5 mg vial | 5 mg vial, 10 mg vial |
| In one line | A GHRH analog studied for growth-hormone-release research, with and without DAC. | A selective growth-hormone-releasing peptide studied for clean GH-pulse research. |
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is studied in two forms: "no DAC" (also called Mod GRF 1-29), which is short-acting, and "with DAC" (Drug Affinity Complex), which binds albumin for a markedly longer half-life in research models.
CJC-1295 research focuses on stimulation of the pituitary to release growth hormone in pulses. The DAC version extends the active window, while the no-DAC version produces a sharper, shorter pulse often studied alongside a GHRP such as Ipamorelin for synergistic release.
What is Ipamorelin?
Ipamorelin is a pentapeptide and a selective growth-hormone secretagogue (a GHRP). In research it is valued for being one of the most selective GHRPs, reported to stimulate GH release with minimal effect on cortisol or prolactin compared with older GHRPs.
Ipamorelin acts on the ghrelin/GH-secretagogue receptor to trigger growth-hormone release. Its selectivity is the central research interest, since it isolates the GH-release variable without confounding hormonal signals.
Key research differences
The two are best understood by what each is studied for. CJC-1295: The DAC form trades fewer administrations for a longer, flatter profile; the no-DAC form is studied for sharper, more physiologic pulses. Choice depends on the research kinetics of interest. Ipamorelin: Compared with GHRP-6 and GHRP-2, Ipamorelin is studied as the most selective option with the least off-target hormonal signaling; compared with Hexarelin it is gentler but less potent.
How researchers choose between them
Because CJC-1295 and Ipamorelin both sit in the growth hormone & muscle category, the choice is a research-design question: match the compound to the exact signal or endpoint your model targets, and in many protocols the two are studied in parallel or in sequence rather than as either/or. Whichever you select, compare on verified quality: both are third-party tested to a 99%+ purity target with a COA on request.
Frequently asked questions
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 a GHRH analog studied for growth-hormone-release research, with and without DAC; Ipamorelin a selective growth-hormone-releasing peptide studied for clean GH-pulse research. Both are growth hormone & muscle research peptides. Both are research-use-only.
Can CJC-1295 and Ipamorelin be studied together?
Yes - within the same category they are often studied in parallel or sequence to compare or combine effects. Any combination work is laboratory research only.
Which is better, CJC-1295 or Ipamorelin?
Neither is universally "better" - the right choice depends on the research question. Match the compound to your model's target signal, and compare suppliers on verifiable third-party purity, not sticker price.
All comparisons · CJC-1295 · Ipamorelin · CJC-1295 cost
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration